National Health (Price and Special Patient Contribution) Amendment Determination 2021 (No. 5) (Cth)
PB 83 of 2021
National Health (Price and Special Patient Contribution) Amendment Determination 2021 (No. 5)
I, Nikolai Tsyganov, Acting Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health and Aged Care, make the following Determination.
Dated 27 July 2021
NIKOLAI TSYGANOV
Acting Assistant Secretary
Pricing and PBS Policy Branch
Technology Assessment and Access Division
Department of Health
Contents
1 Name........................................................................................................................................ 1
2 Commencement........................................................................................................................ 1
3 Authority.................................................................................................................................. 1
4 Schedules................................................................................................................................. 1
Schedule 1—Amendments 2
National Health (Price and Special Patient Contribution) Determination 2021 (PB 35 of 2021) 2
1 Name
This instrument is the National Health (Price and Special Patient Contribution) Amendment Determination 2021 (No. 5).
This instrument may also be cited as PB 83 of 2021.
2 Commencement
(1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.
| Commencement information | ||
| Column 1 | Column 2 | Column 3 |
| Provisions | Commencement | Date/Details |
| 1. The whole of this instrument | 1 August 2021. | |
Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.
(2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.
3 Authority
This instrument is made under section 85B of the National Health Act 1953.
4 Schedules
Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.
Schedule 1—Amendments
National Health (Price and Special Patient Contribution) Determination 2021 (PB 35 of 2021)
1 Schedule 1, entry for Amoxicillin
Omit
| Amoxicillin | Capsule 250 mg (as trihydrate) | Oral | Amoxil | 20 | 1.37 | 4.61 |
| Capsule 500 mg (as trihydrate) | Oral | Amoxil | 20 | 1.63 | 5.12 | |
| Powder for oral suspension 125 mg (as trihydrate) per 5 mL, 100 mL | Oral | Amoxil | 1 | 1.28 | 4.50 | |
| Powder for oral suspension 250 mg (as trihydrate) per 5 mL, 100 mL | Oral | Amoxil Forte | 1 | 1.59 | 4.90 | |
| Powder for paediatric oral drops 100 mg (as trihydrate) per mL, 20 mL | Oral | Amoxil | 1 | 5.88 | 6.37 | |
| Tablet 1 g (as trihydrate) | Oral | Maxamox | 14 | 1.47 | 2.47 |
Substitute
| Amoxicillin | Capsule 250 mg (as trihydrate) | Oral | Amoxil | 20 | 1.37 | 4.61 |
| Capsule 500 mg (as trihydrate) | Oral | Amoxil | 20 | 1.63 | 5.12 | |
| Powder for oral suspension 125 mg (as trihydrate) per 5 mL, 100 mL | Oral | Amoxil | 1 | 1.28 | 4.50 | |
| Powder for oral suspension 250 mg (as trihydrate) per 5 mL, 100 mL | Oral | Amoxil Forte APO-Amoxycillin | 1 1 | 1.59 | 4.90 2.29 | |
| Powder for paediatric oral drops 100 mg (as trihydrate) per mL, 20 mL | Oral | Amoxil | 1 | 5.88 | 6.37 | |
| Tablet 1 g (as trihydrate) | Oral | Maxamox | 14 | 1.47 | 2.47 |
2 Schedule 1, after entry for Amoxicillin with Clavulanic Acid in the form Tablet containing 875 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate)
Insert
| Anastrozole | Tablet 1 mg | Oral | Arimidex | 30 | 11.43 | 16.08 |
3 Schedule 1, after entry for Atenolol in the form Tablet 50 mg
Insert
| Atomoxetine | Capsule 10 mg (as hydrochloride) | Oral | Strattera | 28 | 36.16 | 38.49 |
| Capsule 18 mg (as hydrochloride) | Oral | Strattera | 28 | 36.16 | 38.49 | |
| Capsule 25 mg (as hydrochloride) | Oral | Strattera | 28 | 36.16 | 38.49 | |
| Capsule 40 mg (as hydrochloride) | Oral | Strattera | 28 | 36.16 | 38.49 | |
| Capsule 60 mg (as hydrochloride) | Oral | Strattera | 28 | 36.16 | 38.49 | |
| Capsule 80 mg (as hydrochloride) | Oral | Strattera | 28 | 47.01 | 51.66 | |
| Capsule 100 mg (as hydrochloride) | Oral | Strattera | 28 | 47.01 | 51.66 |
4 Schedule 1, entry for Cefalexin
Omit
| Cefalexin | Capsule 250 mg (as monohydrate) | Oral | Keflex | 20 | 1.59 | 5.09 |
| Capsule 500 mg (as monohydrate) | Oral | Keflex | 20 | 1.73 | 6.82 | |
| Granules for oral suspension 125 mg (as monohydrate) per 5 mL, 100 mL | Oral | Keflex | 1 | 1.82 | 5.68 | |
| Granules for oral suspension 250 mg (as monohydrate) per 5 mL, 100 mL | Oral | Keflex | 1 | 2.10 | 7.39 |
Substitute
| Cefalexin | Capsule 250 mg (as monohydrate) | Oral | APO-Cephalexin Keflex | 20 20 | 1.59 1.59 | 2.29 5.09 |
| Capsule 500 mg (as monohydrate) | Oral | APO-Cephalexin Keflex | 20 20 | 1.73 1.73 | 2.43 6.82 | |
| Granules for oral suspension 125 mg (as monohydrate) per 5 mL, 100 mL | Oral | Keflex | 1 | 1.82 | 5.68 | |
| Granules for oral suspension 250 mg (as monohydrate) per 5 mL, 100 mL | Oral | Keflex | 1 | 2.10 | 7.39 |
5 Schedule 1, entry for Colchicine
(a)omit from the column headed “Determined Price”: 3.70 substitute: 2.78
(b)omit from the column headed “Claimed Price”: 6.40 substitute: 4.80
6 Schedule 1, entry for Duloxetine in the form Capsule 30 mg (as hydrochloride)
omit from the column headed “Claimed Price”: 11.30 substitute: 15.95
7 Schedule 1, entry for Duloxetine in the form Capsule 60 mg (as hydrochloride)
omit from the column headed “Claimed Price”: 12.95 substitute: 17.60
8 Schedule 1, entry for Esomeprazole in the form Tablet (enteric coated) 20 mg (as magnesium trihydrate)
omit from the column headed “Claimed Price”: 9.20 substitute: 10.52
9 Schedule 1, entry for Esomeprazole in the form Tablet (enteric coated) 40 mg (as magnesium trihydrate)
omit from the column headed “Claimed Price”: 13.30 substitute: 14.62
10 Schedule 1, entry for Furosemide
Omit
| Furosemide | Tablet 20 mg | Oral | Lasix‑M | 50 | 0.78 | 1.90 |
| Tablet 40 mg | Oral | Lasix | 100 | 1.56 | 3.79 |
Substitute
| Furosemide | Tablet 20 mg | Oral | Lasix‑M Frusemix-M | 50 100 | 0.78 | 1.90 2.55 |
| Tablet 40 mg | Oral | Lasix | 100 | 1.56 | 3.79 |
11 Schedule 1, after entry for Lercanidipine in the form Tablet containing lercanidipine hydrochloride 20 mg
Insert
| Letrozole | Tablet 2.5 mg | Oral | Femara 2.5 mg | 30 | 18.41 | 23.06 |
12 Schedule 1, after entry for Meloxicam in the form Tablet 15 mg
Insert
| Mercaptopurine | Tablet containing mercaptopurine monohydrate 50 mg | Oral | Purinethol | 25 | 40.15 | 42.01 |
13 Schedule 1, entry for Metoprolol in the form Tablet containing metoprolol tartrate 50 [Brand: Betaloc]
omit from the column headed “Claimed Price”: 9.66 substitute: 11.52
14 Schedule 1, entry for Nizatidine in the form Capsule 150 mg
omit from the column headed “Claimed Price”: 15.86 substitute: 16.77
15 Schedule 1, entry for Nizatidine in the form Capsule 300 mg
omit from the column headed “Claimed Price”: 15.86 substitute: 16.77
16 Schedule 1, after entry for Norethisterone with Ethinylestradiol in the form Pack containing 21 tablets 1 mg‑35 micrograms and 7 inert tablets
Insert
| Nortriptyline | Tablet 10 mg (as hydrochloride) | Oral | Allegron | 50 | 3.55 | 4.05 |
| Tablet 25 mg (as hydrochloride) | Oral | Allegron | 50 | 4.46 | 5.46 |
17 Schedule 1, entry for Olanzapine in the form Tablet 2.5 mg
omit from the column headed “Claimed Price”: 5.37 substitute: 10.03
18 Schedule 1, entry for Olanzapine in the form Tablet 5 mg
omit from the column headed “Claimed Price”: 7.89 substitute: 12.54
19 Schedule 1, entry for Olanzapine in the form Tablet 7.5 mg
omit from the column headed “Claimed Price”: 10.52 substitute: 15.17
20 Schedule 1, entry for Olanzapine in the form Tablet 10 mg
omit from the column headed “Claimed Price”: 13.09 substitute: 17.74
21 Schedule 1, entry for Olanzapine in the form Wafer 5 mg
omit from the column headed “Claimed Price”: 7.89 substitute: 12.54
22 Schedule 1, entry for Olanzapine in the form Wafer 10 mg
omit from the column headed “Claimed Price”: 13.09 substitute: 17.74
23 Schedule 1, entry for Olanzapine in the form Wafer 15 mg
omit from the column headed “Claimed Price”: 18.24 substitute: 22.89
24 Schedule 1, entry for Olanzapine in the form Wafer 20 mg
omit from the column headed “Claimed Price”: 23.39 substitute: 28.04
25 Schedule 1, after entry for Rabeprazole in the form Tablet containing rabeprazole sodium 20 mg (enteric coated)
Insert
| Raloxifene | Tablet containing raloxifene hydrochloride 60 mg | Oral | Evista | 28 | 19.12 | 23.77 |
26 Schedule 1, entry for Spironolactone in the form Tablet 25 mg
omit from the column headed “Claimed Price”: 8.73 substitute: 10.61
27 Schedule 1, entry for Spironolactone in the form Tablet 100 mg
omit from the column headed “Claimed Price”: 19.00 substitute: 20.75
28 Schedule 1, after entry for Sumatriptan in the form Tablet (fast disintegrating) 50 mg (as succinate) [Pricing quantity/pack quantity 4]
Insert
| Tamoxifen | Tablet 20 mg (as citrate) | Oral | Nolvadex-D | 30 | 7.22 | 10.94 |
29 Schedule 1, entry for Zolmitriptan in the form Tablet 2.5 mg
omit from the column headed “Claimed Price”: 6.81 substitute: 7.62
0
0
0